Predictive Total Operating Expenses vs Net Income From Continuing Ops Analysis
POAI Stock | USD 0.78 0.02 2.50% |
Predictive Oncology financial indicator trend analysis is much more than just breaking down Predictive Oncology prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Predictive Oncology is a good investment. Please check the relationship between Predictive Oncology Total Operating Expenses and its Net Income From Continuing Ops accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.
Total Operating Expenses vs Net Income From Continuing Ops
Total Operating Expenses vs Net Income From Continuing Ops Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Predictive Oncology Total Operating Expenses account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have pay attention.
The correlation between Predictive Oncology's Total Operating Expenses and Net Income From Continuing Ops is -0.86. Overlapping area represents the amount of variation of Total Operating Expenses that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of Predictive Oncology, assuming nothing else is changed. The correlation between historical values of Predictive Oncology's Total Operating Expenses and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Operating Expenses of Predictive Oncology are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Total Operating Expenses i.e., Predictive Oncology's Total Operating Expenses and Net Income From Continuing Ops go up and down completely randomly.
Correlation Coefficient | -0.86 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Net Income From Continuing Ops
Most indicators from Predictive Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Predictive Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.As of now, Predictive Oncology's Tax Provision is decreasing as compared to previous years. The Predictive Oncology's current Enterprise Value is estimated to increase to about 12.6 M, while Selling General Administrative is projected to decrease to under 7.1 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 933.7K | 1.0M | 1.1M | 575.4K | Total Revenue | 1.4M | 1.5M | 1.8M | 899.7K |
Predictive Oncology fundamental ratios Correlations
Click cells to compare fundamentals
Predictive Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Predictive Oncology fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 22.4M | 13.1M | 43.8M | 25.7M | 14.4M | 9.5M | |
Short Long Term Debt Total | 5.5M | 5.9M | 879.3K | 180.3K | 2.9M | 1.9M | |
Other Current Liab | 2.4M | 2.9M | 1.4M | 2.1M | 1.6M | 1.6M | |
Total Current Liabilities | 10.9M | 9.3M | 3.2M | 3.9M | 4.0M | 4.0M | |
Total Stockholder Equity | 11.2M | 2.6M | 40.3M | 21.8M | 8.3M | 5.0M | |
Property Plant And Equipment Net | 2.2M | 5.2M | 3.3M | 2.0M | 4.0M | 4.2M | |
Current Deferred Revenue | 40.4K | 53.0K | 187.0K | 602.1K | 308.1K | 323.5K | |
Net Debt | 5.4M | 5.2M | (27.3M) | (21.9M) | (5.9M) | (5.6M) | |
Retained Earnings | (82.5M) | (108.4M) | (128.0M) | (153.8M) | (167.8M) | (159.4M) | |
Accounts Payable | 3.2M | 1.4M | 1.0M | 943.5K | 1.3M | 1.1M | |
Cash | 150.8K | 678.3K | 28.2M | 22.1M | 8.7M | 4.7M | |
Non Current Assets Total | 21.6M | 11.5M | 14.3M | 2.4M | 4.3M | 4.1M | |
Cash And Short Term Investments | 150.8K | 678.3K | 28.2M | 22.1M | 8.7M | 4.7M | |
Common Stock Total Equity | 69.4K | 140.9K | 40.6K | 198.0K | 178.2K | 275.4K | |
Common Stock Shares Outstanding | 143.5K | 597.5K | 2.7M | 3.6M | 4.0M | 4.2M | |
Liabilities And Stockholders Equity | 22.4M | 13.1M | 43.8M | 25.7M | 14.4M | 9.5M | |
Non Current Liabilities Total | 270.3K | 1.1M | 265.1K | 86.1K | 2.2M | 2.3M | |
Other Current Assets | 160.2K | 289.5K | 513.8K | 526.8K | 521.7K | 263.4K | |
Other Stockholder Equity | 93.7M | 110.8M | 167.6M | 174.8M | 176.0M | 184.8M | |
Total Liab | 11.1M | 10.4M | 3.5M | 4.0M | 6.1M | 4.6M | |
Property Plant And Equipment Gross | 2.2M | 3.8M | 3.3M | 4.9M | 7.6M | 7.9M | |
Total Current Assets | 798.3K | 1.5M | 29.5M | 23.4M | 10.1M | 5.5M | |
Short Term Debt | 5.3M | 5.0M | 639.7K | 188.5K | 667.8K | 634.4K | |
Intangible Assets | 3.6M | 3.4M | 4.0M | 253.9K | 252.5K | 239.8K | |
Common Stock | 40.6K | 198.0K | 656.1K | 787.6K | 40.6K | 38.6K | |
Net Receivables | 297.1K | 256.9K | 354.2K | 331.2K | 333.7K | 270.7K | |
Inventory | 190.2K | 289.5K | 387.7K | 430.5K | 494.4K | 299.1K | |
Non Currrent Assets Other | (21.6M) | 116.3K | 167.1K | 75.6K | 124.1K | 130.3K | |
Accumulated Other Comprehensive Income | (273.8K) | (358.8K) | (771.6K) | (792.0) | (712.8) | (748.44) | |
Capital Surpluse | 57.4M | 63.0M | 93.7M | 110.8M | 127.5M | 70.3M | |
Property Plant Equipment | 2.2M | 5.2M | 3.3M | 2.0M | 2.4M | 1.7M | |
Net Tangible Assets | (8.1M) | (3.6M) | 29.4M | 21.5M | 24.7M | 26.0M | |
Net Invested Capital | 16.0M | 7.1M | 40.3M | 21.8M | 8.4M | 15.4M | |
Net Working Capital | (10.1M) | (7.8M) | 26.2M | 19.5M | 6.1M | 5.2M | |
Capital Stock | 76.4K | 198.8K | 656.9K | 788.4K | 41.4K | 39.3K |
Currently Active Assets on Macroaxis
When determining whether Predictive Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Predictive Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Predictive Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Predictive Oncology Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share 0.416 | Quarterly Revenue Growth (0.43) | Return On Assets (0.56) | Return On Equity (1.49) |
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.